| Today’s Big NewsApr 8, 2025 |
|
Home to industry leaders like Amgen and AbbVie, Puerto Rico has over 70 years of pharmaceutical and biotech expertise. With a skilled workforce and world-class infrastructure, it remains a top destination for bioscience innovation. Find out how your company can thrive here.
|
|
| By Gabrielle Masson As President Donald Trump’s massive overhaul of federal agencies continues, several former FDA officials spoke about the potential ramifications for drug reviews and provided a look inside current FDA conditions. |
|
|
|
By James Waldron A U.S. congressional commission has made the case for “swift action” to maintain the nation’s role as a biotech superpower while warning the sector is “dangerously close to falling behind China.” |
By James Waldron The latest biotech to roll out of Third Rock Ventures is working on Fc-based therapeutics it hopes could offer new treatment options to patients with autoimmune disorders like Graves' disease. |
Sponsored by Allucent Project Optimus is changing the landscape of oncology drug development by redefining dose optimization standards. Learn how sponsors can align with FDA expectations and implement more precise dose-finding strategies. Watch the full interview with Alex MacDonald now! |
|
The therapeutic potential of CD34+ cells is virtually limitless. However, the cells themselves can be obtained through several different formats. See which fits your workflow… Learn More >>
|
|
By Nick Paul Taylor Rallybio’s lead program has crashed out. Racing toward a $1.6 billion market, the biotech stopped work on RLYB212 in a rare maternal immune disorder in response to phase 2 data. |
By Zoey Becker Nordic Capital confirmed that it doesn't intend to make an offer for PureTech Health shortly after buyout discussions were disclosed by PureTech. |
By Nick Paul Taylor Johnson & Johnson has reinforced a key plank of its plan to build nipocalimab into a $5 billion medicine, reporting that the benefits seen earlier in a phase 3 autoimmune trial persisted through Week 60 of the open-label extension. |
By Fraiser Kansteiner Less than a year after purchasing private cell therapy company ImmPact Bio to help refresh its ailing CAR-T pipeline, manufacturing considerations have prompted Lyell Immunopharma to cut staff at its new subsidiary and mothball a California facility picked up in the deal. |
By James Waldron As KalVista Pharmaceuticals awaits an FDA decision on sebetralstat, the company has sold the Japanese rights to Kaken for $11 million upfront. |
By Angus Liu Although President Trump’s “Liberation Day” tariffs have spared pharmaceuticals, potential drug-specific import levies remain a sword of Damocles creating anxiety among biopharma companies. Some industry leaders now fear that more than $100 billion in investments could leave the European Union. |
By Kevin Dunleavy Gilead and Roche are continuing to lay off employees in California, with each company revealing a recent round of cuts through the state’s Worker Adjustment and Retraining Notification (WARN) program. While Gilead is eliminating 149 positions at its headquarters in Foster City, Roche is letting go of 108 workers at its Molecular Systems Division in Santa Clara. |
By Zoey Becker The HHS secretary called out the measles vaccines as "the most effective way" to prevent the spread as an outbreak in Texas claims a second life. |
By Noah Tong The Centers for Medicare and Medicaid Services finalized a substantial increase to Medicare Advantage benchmark payments over its advance notice earlier this year. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we dive into our special report ranking the top pharma R&D budgets for 2024. |
|
|---|
|
|
NashBio is transforming life sciences by making complex genomic and real-world data accessible for pharmaceutical R&D. Learn how their innovative Totem platform and groundbreaking Alliance for Genomic Discovery are accelerating research and improving outcomes. By NashBio |
| eBookTypical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence’s release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories’ Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic. Sponsored by: IQVIA |
| WhitepaperAvoid costly mistakes and ensure your clinical development program meets the highest standards by reading WCG’s whitepaper on Imaging Core Labs, Endpoint Adjudication Committees (EAC), and other safety reviews. Sponsored by: WCG |
| Research We interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
